Search DIAN Data Resource Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-D1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 271 - 278 of 278

Investigator:Sylvia Villeneuve

Title:The role of heredity in pre-clinical AD biomarkers: comparison of sporadic AD and autosomal dominant AD

Date of Request:10/25/2016


Aim 1:Compare severity of AD biomarkers changes (including cognition, blood, beta-amyloid and tau CSF, functional and structural MRI; beta-amyloid and tau PET) between asymptomatic individuals with a familial risk of sporadic AD and preclinical ADAD

Aim 2:Compare annual rate of change in AD biomarkers (longitudinal analyses) between asymptomatic individuals with a familial risk of sporadic AD and preclinical ADAD

Aim 3:Assess the influence of other risk factors (APOE, sex, etc.) on AD biomarkers trajectories in both populations

Investigator:Chengjie Xiong, PhD

Title:PreClinical Biomarker Signature RF1

Date of Request:11/4/2016


Aim 1:Integrate the biomarkers and clinical and cognitive databases from ACS+, AIBL, BIOCARD, and WRAP, and develop novel statistical methods for testing the ordering of all biomarkers, both cross-sectionally and longitudinally, to determine which biomarkers indicate the highest likelihood of preclinical

Aim 2:Statistically validate the preclinical stages of AD as proposed by the National Institute on Aging Alzheimer's Association (NIA-AA) Workgroup (Sperling et al. 2011) using data from ACS+, AIBL, BIOCARD, and WRAP, and quantify the amount of preclinical biomarker signature (PBS) through optimum weight

Aim 3:Optimize the design of modern randomized clinical trials (RCTs) in preclinical or early-stage AD by identifying the cognitive composite that minimizes the sample sizes required to adequately power such trials.

Aim 4Assess how MRI white matter hyperintensities, infarcts, microbleeds, Body Mass Index (BMI) & HbA1c contribute to the preclinical changes in biomarkers and cognition, and further neuropathologically validate findings of Aim 1 & 2

Investigator:Mirza Faisal Beg

Title:Characterizing neuroimaging patterns in subjects with MCI progressing to frank AD

Date of Request:11/24/2016


Aim 1:1. To identify neuroimaging biomarkers that can predict the subset of subjects with MCI converting to AD

Aim 2:2. To identify the timing (age) of conversion from MCI to AD by predicting cognitive decline and change in CSF measures

Investigator:Chengjie Xiong

Title:Cross-sectional and Longitudinal Comparison of DIAN MC and those in the ACS on Biomarkers and Cognitions when Baseline Ages are Matched

Date of Request:12/6/2016


Aim 1:To compare DIAN MC to those with a positive family history in the ACS on baseline Biomarkers and Cognitions when their age were matched

Aim 2:To compare DIAN MC to those with a positive family history in the ACS on the longitudinal rates of changes in Biomarkers and Cognitions when their baseline age were matched

Investigator:Elena Rodriguez-Vieitez

Title:Early hypermetabolism in Alzheimer?s disease? Investigating longitudinal multivariate associations between in vivo metabolism, pathophysiology, cognition and genotype

Date of Request:12/23/2016


Aim 1:Test the hypothesis of early hypermetabolism in autosomal dominant AD, and investigate longitudinal multivariate associations between in vivo metabolism, pathophysiology and cognition.

Aim 2:Test how cognitive reserve may modulate the longitudinal associations between in vivo biomarkers and cognition investigated in Aim 1.

Aim 3:Investigate the effect of genotype (familial gene type, mutation type, APOE) on the longitudinal associations investigated in Aims 1 and 2.

Investigator:Mathias Jucker, Johannes Levin, Igor Yakushev

Title:Regional pattern of longitudinal A� accumulation in autosomal dominant Alzheimer's disease

Date of Request:12/31/2016


Aim 1:To investigate regional patterns of longitudinal Aβ accumulation in autosomal dominant AD

Aim 2:To establish a set of target brain regions for antiamyloid clinical trials such as the DIAN-TU

Investigator:Andrew McKenzie

Title:The role of PSEN1 coding mutations on white matter neuroimaging volumes

Date of Request:1/5/2017


Aim 1:Test the hypothesis that individuals with PSEN1 FAD-causative mutations have alterations in their white matter volume sizes compared to individuals without PSEN1 FAD-causative mutations.

Investigator:Josephine Barnes

Title:Baseline volumes and rates of WMH accrual in familial AD: relationships with brain atrophy and cognitive measures

Date of Request:1/26/2017


Aim 1:to quantify WMH accrual in FAD using our longitudinal WMH measurement tool

Aim 2:to assess whether WMH accrual is related to concurrent atrophy of the brain and hippocampus, estimated using the boundary shift integral, and also to change in cognition.

Aim 3:to investigate whether any potential relationships from aims 1) and 2) differ according to genetic status (APP vs. PSEN1 vs. PSEN2).

Aim 4to investigate whether any potential relationships from aims 1) and 2) are materially altered by adjustment for APOE e4 status